Tirbanibulin 1% ointment represents an effective, well-tolerated and innovative field therapy for AK, with a short regimen that fosters adherence and maintains safety even during periods of high UV exposure. The results of this cohort multicenter Italian study endorse tirbanibulin as a compelling therapeutic option throughout the year, including the warmer months. Future prospective studies should further refine follow-up protocols and evaluate the long-term durability of clinical response.
Tirbanibulin 1% real‐world use in 679 actinic keratoses patients during warm season (SUMM‐AK study)
Addari, G.Data Curation
;Atzori, L.Writing – Review & Editing
;
2026-01-01
Abstract
Tirbanibulin 1% ointment represents an effective, well-tolerated and innovative field therapy for AK, with a short regimen that fosters adherence and maintains safety even during periods of high UV exposure. The results of this cohort multicenter Italian study endorse tirbanibulin as a compelling therapeutic option throughout the year, including the warmer months. Future prospective studies should further refine follow-up protocols and evaluate the long-term durability of clinical response.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
tirbanibulina.pdf
accesso aperto
Tipologia:
versione editoriale (VoR)
Dimensione
547.6 kB
Formato
Adobe PDF
|
547.6 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
